Hatim Husain, MD

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes.

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non–small cell lung cancer that has developed resistance to osimertinib.

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024, shedding light on potential strategies for managing EGFR-mutated and MET-amplified non–small cell lung cancer.

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.

Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ongoing research into novel therapeutic strategies and combination approaches to overcome resistance mechanisms.

Discuss emerging data and therapies to optimize future treatment.

Overview of side effects and management when combining these agents.

Highlight key findings in the KRYSTAL-7 trial.

Analyze the appropriate washout period when switching between KRAS inhibitors.

Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.

Address the challenges and recommended approaches for managing the patient’s untreated brain metastases.

Discuss the role of molecular profiling and KRAS G12C testing in guiding treatment decisions of this case.

Assess whether the initial therapy aligned with standard guidelines based on disease stage.

Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of<em> T790M </em>in <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC).